FIGURE 1.

Identification of NLRP4 somatic mutations in patients with advanced non‐small‐cell lung cancer (NSCLC) with a longer progression‐free survival (PFS) following anti‐programmed cell death protein‐1 (PD‐1) treatment. A‐D, Mutation profiles and the PFS of NSCLC patients receiving nivolumab treatment (n = 22) (A,B) or combination therapy (C,D) (n = 9). Arrows indicate patients with NLRP4 mutations. E, Kaplan‐Meier overall survival curves for NSCLC patients (n = 109) with immune checkpoint inhibitor treatment in The Cancer Genome Atlas database. HR, hazard ratio. F, Comparison of serum interferon (IFN)‐α (left) and IFN‐β (right) between responder (R) and nonresponder (NR) groups